Physician profile
Krystyne Doty
NPI 1992258438
$10,428.99
in general payments reported to CMS, 2019-2025
31 companies · $2,566 in 2025
The $2,566 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $2,160 · 2023: $2,315 · 2024: $2,633 · 2025: $2,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,377 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,377.45 |
| Education | $136.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,871.16 | 2021-2025 | Enbrel, Krystexxa, Otezla |
| Abbvie INC. | $1,768.94 | 2021-2025 | |
| Pfizer INC. | $1,734.00 | 2021-2025 | |
| Janssen Biotech, INC. | $1,014.24 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Horizon Therapeutics Plc | $424.29 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $395.58 | 2021-2025 | Saphnelo, Evusheld |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.10 | 2021-2024 | Cyltezo, Ofev |
| Novartis Pharmaceuticals Corporation | $367.23 | 2021-2025 | |
| Radius Health, INC. | $332.98 | 2024-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $308.81 | 2021-2025 | Orencia |
| Lilly USA, LLC | $266.17 | 2021-2025 | Taltz, Olumiant |
| Ucb, INC. | $162.18 | 2021-2025 | Bimzelx, Cimzia |
| Alexion Pharmaceuticals, INC. | $160.28 | 2023-2025 | Strensiq |
| Glaxosmithkline, LLC. | $150.15 | 2021-2025 | Benlysta |
| Kyowa Kirin, INC. | $149.59 | 2023-2025 | Crysvita |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $149.54 | 2022 | |
| Ani Pharmaceuticals, INC. | $141.57 | 2023-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $139.27 | 2023-2025 | Idacio, Tyenne |
| Actelion Pharmaceuticals US, INC. | $105.24 | 2021-2025 | Opsumit, Uptravi |
| Mallinckrodt Hospital Products INC. | $60.93 | 2022-2024 | Acthar |
| Organon LLC | $57.50 | 2021-2024 | Renflexis |
| Aurinia Pharma U.S., INC. | $50.14 | 2021-2024 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $42.90 | 2021-2022 | |
| Mylan Institutional INC. | $35.26 | 2023 | Hulio |
| Sobi, INC | $33.70 | 2024 | |
| Sandoz INC. | $33.49 | 2024 | Hyrimoz |
| Genentech USA, INC. | $28.31 | 2024 | Actemra |
| Celltrion USA INC. | $16.95 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals International, Plc | $16.28 | 2024 | Arcalyst |
| Antares Pharma, INC. | $14.20 | 2021 | |
| Genzyme Corporation | $14.01 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystyne Doty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.